Preventing the transmission of American trypanosomiasis and its spread into non-endemic countries

Infectious Diseases of Poverty

Xiao-Nong Zhou¹  Qin Liu¹ 

[1] National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention; Key Laboratory of Parasite and Vector Biology, Ministry of Health;, WHO Collaborating Center for Tropical Diseases, Shanghai 200025, P. R. China

关键词: Transmission control;    Trypanosoma cruzi;    Chagas disease;    American trypanosomiasis;   

Others  :  1235081
DOI  :  10.1186/s40249-015-0092-7

 received in 2014-12-31, accepted in 2015-12-11,  发布年份 2015

【 摘 要 】

American trypanosomiasis, commonly known as Chagas disease, is caused by the flagellate protozoan parasite Trypanosoma cruzi. An estimated eight million people infected with T. cruzi currently reside in the endemic regions of Latin America. However, as the disease has now been imported into many non-endemic countries outside of Latin America, it has become a global health issue. We reviewed the transmission patterns and current status of disease spread pertaining to American trypanosomiasis at the global level, as well as recent advances in research. Based on an analysis of the gaps in American trypanosomiasis control, we put forward future research priorities that must be implemented to stop the global spread of the disease.

【 授权许可】

   
2015 Liu and Zhou.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]organization WH. Changas disease (American trypanosomiasis) Fact sheet No. 340. Geneva: World Health organization; 2013.. http://www.who.int/mediacentre/factsheets/fs340/en/ webcite
• [2]Moncayo A, Silveira AC: Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009, 104(Suppl 1):17-30.
• [3]Carod-Artal FJ: American trypanosomiasis. Handb Clin Neurol 2013, 114:103-123.
• [4]Schmunis GA, Yadon ZE: Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010, 115:14-21.
• [5]Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O: Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol 2014, 103:1-10.
• [6]Garcia MN, Aguilar D, Gorchakov R, Rossmann SN, Montgomery SP, Rivera H, et al.: Evidence of autochthonous Chagas disease in southeastern Texas. Am J Trop Med Hyg 2015, 92:325-330.
• [7]Isselbacher EM, Kligerman SJ, Lam KM, Hurtado RM: Case records of the Massachusetts General Hospital. Case 2–2010. A 47-year-old man with abdominal and flank pain. N Engl J Med 2010, 362:254-262.
• [8]Riera C, Guarro A, Kassab HE, Jorba JM, Castro M, Angrill R, et al. Congenital transmission of Trypanosoma cruzi in Europe (Spain): a case report. Am J Trop Med Hyg. 2006;75:1078–81.
• [9]Coura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions - A comprehensive review. Mem Inst Oswaldo Cruz. 2014.
• [10]Coura JR, Vinas PA: Chagas disease: a new worldwide challenge. Nature 2010, 465:S6-7.
• [11]Munoz-Calderon A, Diaz-Bello Z, Valladares B, Noya O, Lopez MC, AlarcondeNoya B, et al. Oral transmission of Chagas disease: typing of Trypanosoma cruzi from five outbreaks occurred in Venezuela shows multiclonal and common infections in patients, vectors and reservoirs. Infect Genet Evol. 2013;17:113–22.
• [12]Pereira PC, Navarro EC: Challenges and perspectives of Chagas disease: a review. J Venomous Anim Toxins Incl Trop Dis 2013, 19:34. BioMed Central Full Text
• [13]Alarcon de Noya B, Diaz-Bello Z, Colmenares C, Ruiz-Guevara R, Mauriello L, Zavala-Jaspe R, et al.: Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 2010, 201:1308-1315.
• [14]Rueda K, Trujillo JE, Carranza JC, Vallejo GA. Oral transmission of Trypanosoma cruzi : a new epidemiological scenario for Chagas’ disease in Colombia and other South American countries. Biomedica. 2014;34:631–41.
• [15]Sasagawa E, Guevara de Aguilar AV, Hernandez de Ramirez MA, Romero Chevez JE, Nakagawa J, Cedillos RA, et al. Prevalence of Trypanosoma cruzi infection in blood donors in El Salvador between 2001 and 2011. J Infect Dev Ctries. 2014;8:1029–36.
• [16]Fearon MA, Scalia V, Huang M, Dines I, Ndao M, Lagace-Wiens P: A case of vertical transmission of Chagas disease contracted via blood transfusion in Canada. Can J Infect Dis Med Microbiol 2013, 24:32-34.
• [17]Cevallos AM, Hernandez R: Chagas’ disease: pregnancy and congenital transmission. BioMed Res Int 2014, 2014:401864.
• [18]Imai K, Maeda T, Sayama Y, Mikita K, Fujikura Y, Misawa K, et al.: Mother-to-child transmission of congenital Chagas disease, Japan. Emerg Infect Dis 2014, 20:146-148.
• [19]Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P. Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG. 2014;121:22–33.
• [20]Carlier Y, Sosa-Estani S, Luquetti AO, Buekens P. Congenital Chagas disease: an update. Mem Inst Oswaldo Cruz. 2015.
• [21]Cicora F, Escurra V, Bibolini J, Petroni J, Gonzalez I, Roberti J: Cerebral trypanosomiasis in a renal transplant recipient. Transpl Infect Dis 2014, 16:813-817.
• [22]Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant. 2013;13:2418–25.
• [23]Wallace JA, Miller L, Beavis A, Baptista CA: Chagas disease: a proposal for testing policy for solid-organ transplant in the United States. Prog Transplant 2013, 23:272-277.
• [24]Norman FF, Lopez-Velez R: Chagas disease and breast-feeding. Emerg Infect Dis 2013, 19:1561-1566.
• [25]Kinoshita-Yanaga AT, Toledo MJ, Araujo SM, Vier BP, Gomes ML. Accidental infection by Trypanosoma cruzi follow-up by the polymerase chain reaction: case report. Rev Inst Med Trop Sao Paulo. 2009;51:295–8.
• [26]Schofield CJ, Dias JC: The Southern Cone Initiative against Chagas disease. Adv Parasitol 1999, 42:1-27.
• [27]Yamagata Y, Nakagawa J: Control of Chagas disease. Adv Parasitol 2006, 61:129-165.
• [28]Coura JR, Vinas PA, Junqueira AC. Ecoepidemiology, short history and control of Chagas disease in the endemic countries and the new challenge for non-endemic countries. Mem Inst Oswaldo Cruz. 2014.
• [29]Schofield CJ, Jannin J, Salvatella R: The future of Chagas disease control. Trends Parasitol 2006, 22:583-588.
• [30]organization WH: Informal Consultation on Chagas disease in the Western Pacific (convened by World Health Organization and Regional Office for the Western Pacific), Nagasaki, Japan. 2011.
• [31]Abad-Franch F, Diotaiuti L, Gurgel-Goncalves R, Gurtler RE: Certifying the interruption of Chagas disease transmission by native vectors: cui bono? Mem Inst Oswaldo Cruz 2013, 108:251-254.
• [32]Dias JC, Silveira AC, Schofield CJ: The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002, 97:603-612.
• [33]Coura JR, Junqueira AC: Risks of endemicity, morbidity and perspectives regarding the control of Chagas disease in the Amazon Region. Mem Inst Oswaldo Cruz 2012, 107:145-154.
• [34]Zaniello BA, Kessler DA, Vine KM, Grima KM, Weisenberg SA: Seroprevalence of Chagas infection in the donor population. PLoS Negl Trop Dis 2012, 6:e1771.
• [35]Hashimoto K, Yoshioka K: Certifying achievement in the control of Chagas disease native vectors: what is a viable scenario? Mem Inst Oswaldo Cruz 2014, 109:834-837.
• [36]Coura JR: Chagas disease: control, elimination and eradication. Is it possible? Mem Inst Oswaldo Cruz 2013, 108:962-967.
• [37]Salvatella R, Irabedra P, Castellanos LG: Interruption of vector transmission by native vectors and “the art of the possible”. Mem Inst Oswaldo Cruz 2014, 109:122-125.
• [38]Coura JR, Borges-Pereira J: Chagas disease. What is known and what should be improved: a systemic review. Rev Soc Bras Med Trop 2012, 45:286-296.
• [39]Norman FF, Lopez-Velez R. Mother-to-child transmission of Trypanosoma cruzi infection (Chagas disease): a neglected problem. Trans R Soc Trop Med Hyg. 2014;108:388–90.
• [40]Bonney KM: Chagas disease in the 21st century: a public health success or an emerging threat? Parasite 2014, 21:11.
• [41]Pehrson PO, Wahlgren M, Bengtsson E: Asymptomatic congenital Chagas’ disease in a 5-year-old child. Scand J Infect Dis 1981, 13:307-308.
• [42]Imai K, Maeda T, Sayama Y, Osa M, Mikita K, Kurane I, et al.: Chronic Chagas disease with advanced cardiac complications in Japan: Case report and literature review. Parasitol Int 2015, 64:240-242.
• [43]Requena-Mendez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, et al.: Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis 2015, 9:e0003540.
• [44]Bern C, Montgomery SP: An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009, 49:e52-54.
• [45]Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, et al. Chagas disease in European countries: the challenge of a surveillance system. Euro surveill. 2011;16
• [46]Gascon J, Bern C, Pinazo MJ: Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010, 115:22-27.
• [47]Jackson Y, Pinto A, Pett S: Chagas disease in Australia and New Zealand: risks and needs for public health interventions. Trop Med Int Health 2014, 19:212-218.
• [48]Requena-Mendez A, Albajar-Vinas P, Angheben A, Chiodini P, Gascon J, Munoz J, et al.: Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis 2014, 8:e3245.
• [49]Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL: Chagas disease and the US blood supply. Curr Opin Infect Dis 2008, 21:476-482.
• [50]Organization WH: Control and prevention of Chagas disease in Europe.2009. Geneva, Switzerland. 2009.
• [51]Schijman AG, Altcheh J, Burgos JM, Biancardi M, Bisio M, Levin MJ, et al.: Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother 2003, 52:441-449.
• [52]Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis. 2006;19:583–7.
• [53]Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C: Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. AmJTrop Med Hyg 1998, 59:526-529.
• [54]Duarte LF, Florez O, Rincon G, Gonzalez CI. Comparison of seven diagnostic tests to detect Trypanosoma cruzi infection in patients in chronic phase of Chagas disease. Colomb Med. 2014;45:61–6.
• [55]Reis-Cunha JL, Mendes TA, de Almeida LR, Ribeiro DR, Machado-de-Avila RA, de Oliveira TM, et al. Genome-wide screening and identification of new Trypanosoma cruzi antigens with potential application for chronic Chagas disease diagnosis. PLoS ONE. 2014;9:e106304.
• [56]Enriquez GF, Bua J, Orozco MM, Wirth S, Schijman AG, Gurtler RE, et al. High levels of Trypanosoma cruzi DNA determined by qPCR and infectiousness to Triatoma infestans support dogs and cats are major sources of parasites for domestic transmission. Infect Genet Evol. 2014;25:36–43.
• [57]Escalante H, Jara C, Davelois K, Iglesias M, Benites A, Espinoza R. Western blot technique standardization for specific diagnosis of Chagas disease using excretory-secretory antigens of Trypanosoma cruzi epimastigotes. Rev Peru Med Exp Salud Publica. 2014;31:644–51.
• [58]Castro-Sesquen YE, Gilman RH, Galdos-Cardenas G, Ferrufino L, Sanchez G, Valencia Ayala E, et al.: Use of a novel chagas urine nanoparticle test (chunap) for diagnosis of congenital chagas disease. PLoS Negl Trop Dis 2014, 8:e3211.
• [59]Cardoso RN, Macedo FY, Garcia MN, Garcia DC, Benjo AM, Aguilar D, et al.: Chagas cardiomyopathy is associated with higher incidence of stroke: a meta-analysis of observational studies. J Card Fail 2014, 20:931-938.
• [60]Soeiro Mde N, Dantas AP, Daliry A, Silva CF, Batista DG, de Souza EM, et al.: Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies. Mem Inst Oswaldo Cruz 2009, 104(Suppl 1):301-310.
• [61]Soeiro Mde N, de Castro SL. Screening of potential anti-Trypanosoma cruzi candidates: In Vitro and In Vivo studies. Open Med Chem J. 2011;5:21–30.
• [62]Silva JJ, Guedes PM, Zottis A, Balliano TL, Nascimento Silva FO, Franca Lopes LG, et al.: Novel ruthenium complexes as potential drugs for Chagas’s disease: enzyme inhibition and in vitro/in vivo trypanocidal activity. Br J Pharmacol 2010, 160:260-269.
• [63]Jacobs RT, Plattner JJ, Keenan M: Boron-based drugs as antiprotozoals. Curr Opin Infect Dis 2011, 24:586-592.
• [64]Bustamante JM, Tarleton RL: Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol 2014, 7:317-325.
• [65]Molina I, Salvador F, Sanchez-Montalva A: Posaconazole versus benznidazole for chronic Chagas’ disease. N Engl J Med 2014, 371:966.
• [66]Chatelain E: Chagas disease drug discovery: toward a new era. J Biomol Screen 2015, 20:22-35.
• [67]Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MM, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol. 2012;12:240–53.
• [68]Garcia A, Ortiz S, Iribarren C, Bahamonde MI, Solari A. Congenital co-infection with different Trypanosoma cruzi lineages. Parasitol Int. 2014;63:138–9.
• [69]Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al.: Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014, 14:281-290.
• [70]Reis Machado J, Silva MV, Borges DC, da Silva CA, Ramirez LE, dos Reis MA, et al. Immunopathological aspects of experimental Trypanosoma cruzi reinfections. BioMed Res Int. 2014;2014:648715.
• [71]Hernandez C, Cucunuba Z, Parra E, Toro G, Zambrano P, Ramirez JD. Chagas disease (Trypanosoma cruzi) and HIV co-infection in Colombia. Int J Infect Dis. 2014;26:146–8.
• [72]Ramirez JD, Montilla M, Cucunuba ZM, Florez AC, Zambrano P, Guhl F: Molecular epidemiology of human oral Chagas disease outbreaks in Colombia. PLoS Negl Trop Dis 2013, 7:e2041.
• [73]Martins-Melo FR, Ramos AN Jr, Alencar CH, Heukelbach J: Mortality Related to Chagas Disease and HIV/AIDS Coinfection in Brazil. J Trop Med 2012, 2012:534649.
• [74]Perez CJ, Lymbery AJ, Thompson RC: Chagas disease: the challenge of polyparasitism? Trends Parasitol 2014, 30:176-182.
• [75]Guzman-Bracho C: Epidemiology of Chagas disease in Mexico: an update. Trends Parasitol 2001, 17:372-376.